Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Gonadotropin-releasing hormone (GnRH) antagonists have been widely used for the prevention of
premature luteinizing hormone (LH) surges during controlled ovarian hyperstimulation (COH)
for in vitro fertilization and embryo transfer (IVF-ET) since the late 1990's.
Many years have passed since GnRH antagonists were introduced to prevent premature LH surges
during stimulated cycles. However, there is still no consensus on the optimal GnRH antagonist
protocol. Attempts at modifying GnRH antagonist protocols have been made to improve COH
outcomes. However, a meta-analysis of 27 randomized controlled trials, including recent
reports, showed significantly lower clinical ongoing pregnancy rates in the antagonist group.
Thus, additional efforts are needed to identify the optimal stimulation protocols to achieve
better follicular and embryonic development and to improve the pregnancy rates in COH using
GnRH antagonist.
Given the assumption of a detrimental effect of GnRH antagonist on the pregnancy rate, with
current protocols, we hypothesized that a shorter duration of GnRH antagonist administration
might improve outcome.